What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients?

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 3, 2016, Pages 696-702

  Alobaid, Abdulaziz S ^a   Brinkmann, Alexander ^b   Frey, Otto R ^b   Roehr, Anka C ^b   Luque, Sonia ^c,d   Grau, Santiago ^c,d   Wong, Gloria ^a   Abdul Aziz, Mohd Hafiz ^a   Roberts, Michael S ^e   Lipman, Jeffrey ^a,f,g   Roberts, Jason A ^a,f  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Hospital of Heidenheim   (Germany)

^c HOSPITAL DEL MAR   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e QUEEN ELIZABETH HOSPITAL   (Australia)

^f ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^g QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MEROPENEM; PIPERACILLIN; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

ADULT; AGE; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE CLEARANCE; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; OBESITY; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; SEX DIFFERENCE; TREATMENT DURATION; VOLUME OF DISTRIBUTION; ADOLESCENT; AUSTRALIA; CHEMISTRY; DRUG EFFECTS; GERMANY; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; PLASMA; SPAIN; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AUSTRALIA; CRITICAL ILLNESS; FEMALE; GERMANY; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OBESITY; PIPERACILLIN; PLASMA; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDIES; SPAIN; THIENAMYCINS; YOUNG ADULT;

EID: 84960798509     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv412     Document Type: Article

References (29)

1. Roberts JA, Norris R, Paterson DL et al. Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol 2012; 73: 27-36.
2. Roberts JA, Roberts MS, Semark A et al. Antibiotic dosing in the 'at risk' critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients. BMC Anesthesiol 2011; 11: 3.
3. Wong G, Brinkman A, Benefield RJ et al. An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units. J Antimicrob Chemother 2014; 69: 1416-23.
4. De Waele JJ, Carrette S, Carlier M et al. Therapeutic drug monitoringbased dose optimisation of piperacillin and meropenem: a randomised controlled trial. Intensive Care Med 2014; 40: 380-7.
5. De Waele JJ, Lipman J, Akova M et al. Risk factors for target nonattainment during empirical treatment with β-lactam antibiotics in critically ill patients. Intensive Care Med 2014; 40: 1340-51.
6. Pai MP, Cojutti P, Pea F. Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe Gram-negative bacterial infections. Clin Pharmacokinet 2015; 54: 933-41.
7. Hites M, Taccone FS, Wolff F et al. Case-control study of drug monitoring of β-lactams in obese critically ill patients. Antimicrob Agents Chemother 2013; 57: 708-15.
8. Hites M, Taccone FS, Wolff F et al. Broad-spectrum β-lactams in obese non-critically ill patients. Nutrit Diab 2014; 4: e119.
9. Kays MB, Fleming MR, Cheatham SC et al. Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients. Ann Pharmacother 2014; 48: 178-86.
10. Abhyankar S, Leishear K, Callaghan FM et al. Lower short-and longterm mortality associated with overweight and obesity in a large cohort study of adult intensive care unit patients. Crit Care 2012; 16: R235.
11. Kiraly L, Hurt RT, Van Way CW 3rd. The outcomes of obese patients in critical care. JPEN 2011; 35: 29S-35S.
12. Sime FB, Roberts MS, Peake SL et al. Does β-lactam pharmacokinetic variability in critically ill patients justify therapeutic drug monitoring? A systematic review. Ann Intensive Care 2012; 2: 35.
13. Longo C, Bartlett G, Macgibbon B et al. The effect of obesity on antibiotic treatment failure: a historical cohort study. Pharmacoepidemiol Drug Saf 2013; 22: 970-6.
14. Sturm AW, Allen N, Rafferty KD et al. Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients. Pharmacother 2014; 34: 28-35.
15. Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacother 2007; 27: 1081-91.
16. Boucher BA, Wood GC, Swanson JM. Pharmacokinetic changes in critical illness. Crit Care Clin 2006; 22: 255-71.
17. Legrand M, Payen D. Understanding urine output in critically ill patients. Ann Intensive Care 2011; 1: 13.
18. Schiffl H, Lang SM. Earlier diagnosis of acute kidney injury in critically ill patients by novel biomarkers: moving from supportive care to targeted renoprotection? Crit Care 2013; 1: 1-6.
19. Roberts JA, Abdul-Aziz MH, Lipman J et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 2014; 14: 498-509.
20. Hites M, Taccone FS. Optimization of antibiotic therapy in the obese, critically ill patient. Réanimation 2015; 24: 278-94.
21. Roberts JA, De Waele JJ, Dimopoulos G et al. DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic. BMC Infect Dis 2012; 12: 152.
22. Wong G, Briscoe S, Adnan S et al. Protein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? Antimicrob Agents Chemother 2013; 57: 6165-70.
23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
24. Li C, Du X, Kuti JL et al. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 2007; 51: 1725-30.
25. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10; quiz 11-2.
26. Sinnollareddy M, Lipman J, Roberts MS et al. β-Lactam pharmacokinetics/pharmacodynamics in critically ill patients and strategies for dose-optimisation-astructured review. Clin Exp Pharmacol Physiol 2012; 39: 489-96.
27. Cheatham SC, Fleming MR, Healy DP et al. Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese patients hospitalized in an intensive care unit. J Clin Pharmacol 2014; 54: 324-30.
28. Cheatham SC, Fleming MR, Healy DP et al. Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients. Int J Antimicrob Agents 2013; 41: 52-6.
29. Udy AA, Varghese JM, Altukroni M et al. Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 2012; 142: 30-9.